JP2022542222A5 - - Google Patents

Info

Publication number
JP2022542222A5
JP2022542222A5 JP2021578171A JP2021578171A JP2022542222A5 JP 2022542222 A5 JP2022542222 A5 JP 2022542222A5 JP 2021578171 A JP2021578171 A JP 2021578171A JP 2021578171 A JP2021578171 A JP 2021578171A JP 2022542222 A5 JP2022542222 A5 JP 2022542222A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
amino acid
acid sequence
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021578171A
Other languages
English (en)
Japanese (ja)
Other versions
JP7407845B2 (ja
JP2022542222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/094767 external-priority patent/WO2020259258A1/zh
Publication of JP2022542222A publication Critical patent/JP2022542222A/ja
Publication of JP2022542222A5 publication Critical patent/JP2022542222A5/ja
Application granted granted Critical
Publication of JP7407845B2 publication Critical patent/JP7407845B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021578171A 2019-06-28 2020-06-05 抗体薬物複合体、その中間体、製造方法及び使用 Active JP7407845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910577909.6 2019-06-28
CN201910577909 2019-06-28
PCT/CN2020/094767 WO2020259258A1 (zh) 2019-06-28 2020-06-05 一种抗体偶联药物、其中间体、制备方法及应用

Publications (3)

Publication Number Publication Date
JP2022542222A JP2022542222A (ja) 2022-09-30
JP2022542222A5 true JP2022542222A5 (cg-RX-API-DMAC7.html) 2023-06-26
JP7407845B2 JP7407845B2 (ja) 2024-01-04

Family

ID=74059658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021578171A Active JP7407845B2 (ja) 2019-06-28 2020-06-05 抗体薬物複合体、その中間体、製造方法及び使用

Country Status (9)

Country Link
US (1) US20220233708A1 (cg-RX-API-DMAC7.html)
EP (1) EP3991754A4 (cg-RX-API-DMAC7.html)
JP (1) JP7407845B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220025861A (cg-RX-API-DMAC7.html)
CN (1) CN113766933B (cg-RX-API-DMAC7.html)
AU (1) AU2020301289B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026580A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144790A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020259258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230054458A1 (en) * 2019-12-12 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
WO2021252708A1 (en) * 2020-06-11 2021-12-16 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
JP7753372B2 (ja) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
EP4257153B1 (en) * 2020-12-04 2025-11-12 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
CN116583526B (zh) * 2020-12-11 2025-09-26 微境生物医药科技(上海)有限公司 新型喜树碱衍生物、含其的组合物和其用途
JP7564958B2 (ja) * 2020-12-18 2024-10-09 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用
EP4265275A4 (en) * 2020-12-18 2024-03-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ANTIBODY-DRUG CONJUGATE TARGETING TROP2, PREPARATION METHOD AND USE THEREOF
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2022171115A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 用于adc制备的喜树碱衍生物
CN116897149A (zh) * 2021-03-30 2023-10-17 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116867789B (zh) * 2021-03-31 2025-06-24 上海复旦张江生物医药股份有限公司 一种伊喜替康衍生物的制备方法及其中间体
CN115385926B (zh) * 2021-05-24 2025-06-03 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
IL309457A (en) * 2021-06-17 2024-02-01 Minghui Pharmaceutical Hangzhou Ltd Compound against tumors and its use
CN117715913A (zh) * 2021-07-19 2024-03-15 芝诺管理公司 免疫缀合物和方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
WO2023006084A1 (zh) 2021-07-30 2023-02-02 上海复旦张江生物医药股份有限公司 一种抗dll3抗体及其制备方法、其药物偶联物和应用
MX2024003277A (es) * 2021-09-15 2024-04-04 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
KR20240082348A (ko) * 2021-09-27 2024-06-10 에보포인트 바이오사이언시스 컴퍼니 리미티드 항체, 이의 항체-약물 접합체 및 이의 용도
CN118401258A (zh) * 2021-12-09 2024-07-26 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2024008102A1 (en) * 2022-07-05 2024-01-11 Wuxi Xdc (Shanghai) Co., Ltd. Linker for conjugation
EP4558506A1 (en) * 2022-07-22 2025-05-28 NJ Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
JP2025524970A (ja) * 2022-07-27 2025-08-01 明慧医藥（杭州）有限公司 抗体－薬物コンジュゲートおよびその使用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
KR20250111373A (ko) * 2022-11-25 2025-07-22 밍훼이 파마슈티컬 (항저우) 리미티드 항종양 화합물 및 이의 응용
WO2024114667A1 (zh) * 2022-11-30 2024-06-06 正大天晴药业集团股份有限公司 抗cldn18.2抗体药物偶联物及其药物组合物和用途
CN116178386B (zh) 2022-12-30 2025-09-09 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116217655B (zh) * 2022-12-30 2025-09-23 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的中间体的制备方法
CN116217654B (zh) * 2022-12-30 2025-09-26 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
JPWO2024214685A1 (cg-RX-API-DMAC7.html) 2023-04-10 2024-10-17
WO2025021152A1 (zh) * 2023-07-26 2025-01-30 上海医药集团股份有限公司 喜树碱类小分子及其抗体药物偶联物、制备方法和应用
WO2025049270A1 (en) * 2023-08-25 2025-03-06 Macrogenics, Inc. B7-h3 antibody-drug conjugates
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
CN120617538B (zh) * 2025-07-21 2026-04-03 南京滴力生物科技有限公司 一种用于治疗肿瘤的抗体药物偶联物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2240495B1 (en) * 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
NZ610239A (en) * 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
ES2647317T3 (es) * 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
WO2013173337A2 (en) * 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
ES2773710T3 (es) * 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
EP3209334A2 (en) * 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
EP4321523A3 (en) * 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
WO2019034176A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CN109200291B (zh) * 2018-10-24 2021-06-08 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途

Similar Documents

Publication Publication Date Title
JP2022542222A5 (cg-RX-API-DMAC7.html)
TWI868726B (zh) 抗體-藥物結合物之新穎製造方法
JP7754361B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2023510905A5 (cg-RX-API-DMAC7.html)
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
CN112261954A (zh) 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
JP2022532918A5 (cg-RX-API-DMAC7.html)
CN113194983A (zh) 用于治疗病毒感染的组合物及方法
CN1045089C (zh) 2－(2－氨基－1,6－二氢－6－氧代－嘌呤－9－基)甲氧基－1,3－丙二醇衍生物
JP2013500304A5 (cg-RX-API-DMAC7.html)
WO2022199237A1 (zh) 修饰的氨基酸及其在adc中的应用
JP2022507781A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
JP2024546497A5 (cg-RX-API-DMAC7.html)
JP2025503493A5 (cg-RX-API-DMAC7.html)
WO2024130161A2 (en) Novel camptothecin derivatives and conjugates thereof
JP2024088768A5 (cg-RX-API-DMAC7.html)
AU2022234694A9 (en) Compound or salt thereof, and antibody obtained using same
BR112021001992A2 (pt) efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
JP2019524845A5 (cg-RX-API-DMAC7.html)
WO2024119049A1 (en) Compositions and methods for protein internalization
TWI820038B (zh) 妥布賴森(tubulysins)及其中間產物之製備方法
TWI825169B (zh) 妥布賴森(tubulysins)及其中間體之製備之替代方法
WO2019168164A1 (ja) タンパク質及び／又はペプチド修飾用分子